Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $73.38

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned a consensus rating of “Buy” from the ten research firms that are presently covering the firm, MarketBeat reports. Ten equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $73.38.

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. BMO Capital Markets started coverage on Jasper Therapeutics in a report on Friday. They set an “outperform” rating and a $63.00 target price for the company. JMP Securities reiterated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Finally, Evercore ISI restated an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds have recently modified their holdings of the company. Samsara BioCapital LLC increased its holdings in Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after acquiring an additional 59,642 shares in the last quarter. Ally Bridge Group NY LLC grew its stake in Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after acquiring an additional 180,852 shares in the last quarter. Braidwell LP acquired a new stake in Jasper Therapeutics in the 3rd quarter valued at about $9,091,000. Bank of New York Mellon Corp acquired a new stake in shares of Jasper Therapeutics in the second quarter valued at approximately $740,000. Finally, American Century Companies Inc. lifted its position in Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares in the last quarter. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Trading Down 0.4 %

Shares of NASDAQ JSPR opened at $22.40 on Friday. Jasper Therapeutics has a 12-month low of $4.00 and a 12-month high of $31.01. The firm’s 50-day moving average price is $20.62 and its 200-day moving average price is $20.89. The stock has a market capitalization of $336 million, a price-to-earnings ratio of -4.73 and a beta of 2.18.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.